This case presents a genuine tension between the letter of a protective law and the immediate protection of a life. The resolution is not to choose between law and life — it is to recognise that the law itself provides the mechanism for resolution.

(1) Ethical issues: Four bioethical dimensions intersect here. Non-maleficence: allowing the woman to bleed out is the greater harm; the blood bank law's protective purpose (preventing incompatible or infected blood) can be served with the field testing equipment present in the ambulance. Beneficence: the DM has both the legal authority and the medical training to make this decision actively — passivity in the name of legal compliance is not beneficence. Autonomy: the woman's informed consent is required and achievable — she must understand what is being proposed and agree. Justice: Art. 21 and the Paschim Banga (1996) judgment affirm that every person, including a pregnant woman at a disaster site, has the right to emergency medical care.

(2) Options: Strict legal refusal means the woman dies of a preventable condition — this is the outcome the law was never designed to produce, and it cannot be the answer. Proceeding informally without authorisation exposes the medical team to professional liability — and they correctly require formal protection before acting. The most appropriate option is to issue a formal written emergency order under the Disaster Management Act, 2005 (Sections 30, 33, 34), which confer extraordinary powers on district authorities in disaster situations. The order documents: the life-threatening medical necessity, the availability of blood group compatibility testing equipment, the trained personnel present, the impossibility of transport, and the patient's consent. This is not bypassing the law — it is using the law's own emergency mechanism. Simultaneously, dispatch the nearest blood bank's mobile unit to the site.

The key insight: The blood bank requirement exists to prevent incompatible or infected blood from reaching patients. With testing equipment available and trained physicians present, the requirement's protective purpose can be fully served in the field. The law requires compatible, tested blood administered by trained personnel — not a specific building. A DM emergency order converts this recognition into legally protected action.

(a) What I would do: Refuse all three shortcuts — not as a collective package but individually, since each one independently crosses a line that medical ethics cannot accept. Document the pressure from senior members in writing to the institutional ethics committee (IEC) — this creates a record and invokes the IEC's authority to adjudicate the dispute. Present alternative legitimate pathways for accelerating the timeline without compromising ethics.

(b) Ethical consequences of each shortcut:

Data manipulation: When a drug reaches patients based on manipulated trial data, those patients are treated on the basis of a systematic lie. Undisclosed adverse effects will manifest at scale — this is the Thalidomide lesson. Beyond direct patient harm, data manipulation destroys the reproducibility of the trial — other researchers cannot build on falsified foundations, setting back the science for all subsequent treatments. Under the Drugs and Cosmetics Act and ICMR Guidelines 2017, data manipulation in drug trials is criminal, not merely unethical.

Skipping informed consent: Informed consent is the patient's right to decide what happens to their own body — the Nuremberg Code's foundational principle. Skipping it converts trial participants into means for commercial ends. No first-mover advantage justifies treating human beings as experimental subjects without their knowledge and agreement. Emergency consent protocols exist for urgent situations — they must be used, not circumvented.

Using patented compound without authorisation: Patent infringement with a public health justification is not self-authorising — it converts a legitimate emergency into a criminal act that also invalidates the trial's scientific record. The Doha Declaration and Patents Act s.84 compulsory licensing provisions exist for exactly this situation. The correct path is to apply for emergency compulsory licensing — not to steal.

(c) How data ethics and drug ethics save humanity: Trust in medical research is a global public good — it is the foundation on which vaccine programmes, pandemic responses, and chronic disease treatments rest. When COVID-19 vaccines were developed at unprecedented speed, they were accepted by billions of people because the research community had built decades of trust through rigorous data integrity and transparent trial design. That trust is not permanent — it is rebuilt or destroyed by each research decision. Data ethics saves humanity not by slowing medicine down but by ensuring that medicine can be trusted. Drug ethics ensures that the treatments that reach patients actually do what they claim. Without both, the speed of research produces no benefit — only faster harm at scale.

Legitimate alternatives for acceleration: Adaptive trial design (allows real-time protocol modification based on interim results — CDSCO approved for emergencies). Emergency use authorisation (EUA) pathway — grants provisional approval for unmet medical needs while full trial continues. Compassionate use / expanded access protocols for severe cases while the main trial proceeds. These mechanisms were designed precisely to balance speed with safety — they are not bureaucratic obstacles but carefully designed solutions to exactly this dilemma.